Acasti Pharma Gross Profit 2014-2024 | GRCE

Acasti Pharma gross profit from 2014 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Acasti Pharma Annual Gross Profit
(Millions of US $)
2024 $
2023 $
2022 $
2021 $0
2020 $
2019 $
2018 $
2017 $
2016 $-0
2015 $-0
2015 $
2014 $0
2014 $
2013 $0
2013 $
Acasti Pharma Quarterly Gross Profit
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31 $0
2020-12-31 $0
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-02-28
2016-11-30 $0
2016-08-31 $0
2016-05-31 $0
2016-03-31 $0
2016-02-29 $-0
2015-12-31 $-0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2014-02-28
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00